Align Technology Stock Outlook: Is Wall Street Bullish or Bearish?
/Align%20Technology%2C%20Inc_%20phone%20and%20website-by%20T_Schneider%20via%20Shutterstock.jpg)
Tempe, Arizona-based Align Technology, Inc. (ALGN) designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists. Valued at $12.4 billion by market cap, the company also manufactures software for dental laboratories and dental practitioners.
Shares of this leading manufacturer of clear aligners have underperformed the broader market over the past year. ALGN has declined 30.2% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 11.6%. In 2025, ALGN’s stock fell 14.4%, compared to the SPX’s marginal gains on a YTD basis.
Narrowing the focus, ALGN’s underperformance is also apparent compared to the SPDR S&P Health Care Equipment ETF (XHE). The exchange-traded fund has declined about 4.6% over the past year. Moreover, the ETF’s 7% losses on a YTD basis outshine the stock’s double-digit dip over the same time frame.
On Apr. 30, ALGN shares closed down by 2.5% after reporting its Q1 results. Its adjusted EPS of $2.13 beat Wall Street expectations of $1.98. The company’s revenue was $979.3 million, beating Wall Street forecasts of $972.8 million. For Q2, ALGN expects revenue in the range of $1.05 billion to $1.07 billion.
For the current fiscal year, ending in December, analysts expect ALGN’s EPS to grow 19.5% to $8.38 on a diluted basis. The company’s earnings surprise history is disappointing. It missed the consensus estimate in three of the last four quarters while beating the forecast on another occasion.
Among the 13 analysts covering ALGN stock, the consensus is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, one “Moderate Buy,” two “Holds,” and one “Moderate Sell.”
The configuration is consistent over the past three months.
On May 15, Evercore ISI analyst Elizabeth Anderson CFA maintained a “Buy” rating on ALGN with a price target of $200, implying a potential upside of 12% from current levels.
The mean price target of $234.25 represents a 31.2% premium to ALGN’s current price levels. The Street-high price target of $275 suggests a notable upside potential of 54%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.